Targazyme

company

About

Targazyme is a bio-pharmaceutical company that develops and commercializes breakthrough products.

  • 1 - 10

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$2.50M
Industries
Biopharma,Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2005
Number Of Employee
1 - 10
Operating Status
Active

Targazyme, Inc. (formerly America Stem Cell, Inc.) is a clinical-stage biopharmaceutical company developing and commercializing breakthrough products designed to improve outcomes for patients receiving cell therapy. Our most advanced product, TZ101, improves the therapeutic potential of cells by enhancing migration to selective sites in the body and improving retention in tissue. This will increase the effectiveness of the cells in numerous disease indications.

Target indications for the Company’s products include cancer, ischemic diseases like heart failure, critical limb ischemia and diabetic retinopathy, and radiation sickness, each of which represents a large market with significant opportunity to improve outcomes for patients. The company was founded in 2005 and has received funding from angel investors, the management team, and several non-profit and governmental institutions.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$2.50M
Targazyme has raised a total of $2.50M in funding over 2 rounds. Their latest funding was raised on Jul 15, 2009 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 15, 2009 Series Unknown $2.50M 1 Texas Wide Open for Business Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Targazyme is funded by 1 investors. Texas Wide Open for Business are the most recent investors.
Investor Name Lead Investor Funding Round
Texas Wide Open for Business Yes Series Unknown